Dr. Lovly reported that maintenance lurbinectedin + atezolizumab in extensive‑stage SCLC (INFORTE) improved PFS (5.4 vs 2.1 mo) and OS (13.2 vs 10.6 mo), while second‑line tarlatumab (DELPHI‑304) lifted OS to 13.6 vs 8.3 mo. She further highlighted that neoadjuvant chemo‑nivolumab (CheckMate 816) boosted 5‑year OS to 65 % with higher pCR, and that administering immunotherapy before 3 p.m. enhances PFS and OS, underscoring regimen choice and treatment timing as key advances in lung‑cancer care.